Evidence map›Paper›PMID 28855513›Full record

ArticleScientific reports2017

Noninvasive Imaging of Ras Activity by Monomolecular Biosensor Based on Split-Luciferase Complementary Assay.

Liang Chen, Wei Bing Leng, De Zhi Li, Hong Wei Xia, Min Ren, Qiu Lin Tang, Qi Yong Gong, Fa Bao Gao, Feng Bi

Abstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Frontiers in cell and developmental biology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Liang ChenLaboratory of Molecular Targeted Therapy in Oncology, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan, China.
Wei Bing LengLaboratory of Molecular Targeted Therapy in Oncology, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan, China.
De Zhi LiLaboratory of Molecular Targeted Therapy in Oncology, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan, China.
Hong Wei XiaLaboratory of Molecular Targeted Therapy in Oncology, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan, China.
Min RenLaboratory of Molecular Targeted Therapy in Oncology, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan, China.
Qiu Lin TangLaboratory of Molecular Targeted Therapy in Oncology, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan, China.
Qi Yong GongDepartment of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Fa Bao GaoDepartment of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Feng BiLaboratory of Molecular Targeted Therapy in Oncology, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan, China. bifeng@medmail.com.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Deregulated activity of Ras GTPases has been observed in many types of human cancers, and contributes to the diverse aspects of carcinogenesis. Although the significance in tumorigenesis has been widely accepted and many therapeutic drugs are under development, little attention has been dedicated to the development of sensors for the Ras activity in vivo. Therefore, based on the split firefly luciferase complementation strategy, we developed a monomolecular bioluminescent biosensor to image endogenous Ras activity in living subject. In this biosensor, two inactive luciferase fragments are sandwiched by Raf-1, whose conformation changes upon GTP-Ras binding. Thus, the Ras activity can be surrogated by the intensity of the complementary luciferase. The bioluminescence analyses demonstrated that this novel biosensor behaved the robust and sensitive reporting efficiency in response to the dynamical changes of Ras activity, both in living colorectal cancer cells and in vivo. Compared to the traditional method, such as the pull-down assay, the bioluminescent sensor is simply, noninvasive, faster and more sensitive for the analysis of the endogenous Ras activity. This innovative work opens up the way for monitoring the preclinical curative effect and high-throughput screening of therapeutic drugs targeting Ras pathways.

Indexed as

Biosensing TechniquesCell Line, TumorHumansIntravital MicroscopyLuciferasesLuminescent AgentsLuminescent Measurementsras ProteinsLuciferasesLuminescent Agentsras Proteins

Identifiers

PMID28855513
PMCPMC5577193

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.